SGLT-2 inhibitors linked to lower chronic lower respiratory disease risk in type 2 diabetes
Two target trial emulations using Shenzhen health data found SGLT-2 inhibitor users had a lower incidence of chronic lower respiratory disease than users of GLP-1 receptor agonists or DPP-4 inhibitors.
“Compared with GLP-1 RA, SGLT-2i were associated with a significantly lower risk of CLRDs, driven predominantly by bronchitis”— Yuhao Li, Yiqiao Lv, Yongqi Dai et al.
Adults with type 2 diabetes who used sodium-glucose cotransporter 2 inhibitors (SGLT-2i) had a lower incidence of chronic lower respiratory disease (CLRD) than users of two other drug classes, according to a study in Respiratory Research.
The researchers, led by Yuhao Li, Yiqiao Lv and Yongqi Dai, used the Shenzhen Public Health Data Platform. They ran two independent target trial emulations with a new-user active comparator design, comparing SGLT-2i with glucagon-like peptide-1 receptor agonists (GLP-1RA) and with dipeptidyl peptidase-4 inhibitors (DPP-4i). The primary outcome was incident CLRD. Secondary outcomes were bronchitis, bronchiectasis, asthma, chronic obstructive pulmonary disease and emphysema. Hazard ratios were estimated with overlap-weighted Cox models.
Over a median follow-up of 1.76 years, new CLRD cases occurred in 349 SGLT-2i users (7.95%) and 397 GLP-1RA users (9.04%). Against GLP-1RA, SGLT-2i use was associated with lower CLRD incidence (HR 0.87, 95% CI 0.79-0.96). The authors said this was driven mainly by bronchitis (HR 0.89, 95% CI 0.79-1.00) and asthma (HR 0.77, 95% CI 0.58-1.01). No significant associations were found for the other subtypes.
Against DPP-4i, SGLT-2i use showed a trend toward lower CLRD risk (HR 0.95, 95% CI 0.91-0.99). Reductions were reported for bronchitis (HR 0.95, 95% CI 0.91-1.00), bronchiectasis (HR 0.86, 95% CI 0.75-1.00) and asthma (HR 0.87, 95% CI 0.77-0.98).
Subgroup analyses showed a significant interaction by sex for bronchiectasis (P interaction = 0.001). Relative to DPP-4i, the association between SGLT-2i use and lower bronchiectasis risk was more pronounced in women than in men.